Blockade of endogenous interleukin 12 results in suppression of murine streptococcal cell wall arthritis by enhancement of interleukin 10 and interleukin 1 Ra

Annals of the Rheumatic Diseases

Volumn 59, Issue 3, 2000, Pages 196-205

  Joosten, Leo A B ^a   Helsen, Monique M A ^a   Van Den Berg, Wim B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL ARTHRITIS; BACTERIAL CELL WALL; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATORY CELL; KILLER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, INFECTIOUS; CELL WALL; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-10; INTERLEUKIN-12; MALE; MICE; MICE, INBRED C57BL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIALOGLYCOPROTEINS; STREPTOCOCCUS PYOGENES;

EID: 0034078763     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.59.3.196     Document Type: Article

References (52)

1. 1 Stern AS, Podlaski FJ, Hulmes JD, Pan EY, Quinn PM, Wolitzki AG, et al. Purification of homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 1990;87:6808-12.
2. 2 Kobayashi M, Fitz L, Ryan M, Hewick SC, Clark SC, Chan SH, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989;170:827-45.
3. 3 D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, et al. Production of natural killer cell stimulatory factor (interleukin-12) by peripheral blood mononuclear cells. J Exp Med 1992;176:1387-98.
4. 4 Gazzinelli RT, Hieny S, Wynn TA, Wolf SF, Sher A. IL-12 is required for the T-lymphocyte-independent induction of interferon-gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci USA 1993;90:6115-19.
5. + T-cells to enhance priming for interferon-γ production and diminished interleukin-4 inhibition of such priming. Proc Natl Acad Sci USA 1993;90: 10188-92.
6. 6 Abbas AK, Murphy K M, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-93.
7. 7 Wysocka M, Kubin M, Vieira LQ, Ozmen L, Garotta G, Scott P, et al. Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice. Eur J Immunol 1995;25:672-6.
8. 8 Ozmen L, Pericin M, Hakimi J, Chizzonite RA, Wysocka M, Trinchieri G, et al. Interleukin-12, interferon gamma and tumor necrosis factor alpha are the key cytokines of the generalized Shwartzman reaction. J Exp Med 1994;180: 907-15.
9. 9 Trinchieri G. IL-12: a proinflammatory cytokine with immunoregulatory functions that bridges innate resistance and antigen specific adaptive immunity. Annu Rev Immunol 1995;13:251-76.
10. 10 Mattner F, Magram J, Ferrante J, Launois P, Di Padova K, Behin R, et al. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 1996;26:1553-9.
11. 11 Magram J, Connaughton SE, Warrier RR, Carvajal DM, Wu C-Y, Ferrante J, et al. IL-12 deficient mice are defective in IFN-γ production and type I cytokine responses. Immunity 1996;4:471-81.
12. 12 Segal BM, Shevach EM. IL-12 unmasks autoimmune disease in resistance mice. J Exp Med 1996;184:771-5.
13. 13 Chen E, Keystone EC, Fish EN. Restricted cytokine expression in rheumatoid arthritis. Arthritis Rheum 1993;36: 901-10.
14. 14 Morita Y, Yamamura M, Nishida K, Harada S, Okamoto H, Inoue M, et al. Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis Rheum 1998;41:306-14.
15. 15 Cromartie WJ, Craddock JG, Schwab JH, Anderle SK, Yang C. Arthritis in rats after systemic injection of streptococcal cells or cell wall. J Exp Med 1977;146:1585-602.
16. 16 Schrier DJ, Schimmer RC, Flory DM, Tung DK, Ward PA. Role of chemokines and cytokines in a reactivation model of arthrtis induced by injection with streptococcal cell walls. J Leukoc Biol 1998;63:359-63.
17. 17 Van den Broek MF, van den Berg WB, van de Putte LBA, Severijnen AJ. Streptococcal cell wall induced arthritis and flare-up reactions in mice induced by homologous and heterologous cell walls. Am J Pathol 1988;133:139-49.
18. 18 Kuiper S, Joosten LAB, Bendele AM, Edwards III CK, Arntz OJ, Helsen MMA, et al. Different roles tumour necrosis factor α and interleukin-1 in murine streptococcal cell wall arthritis. Cytokine 1998;10:690-702.
19. 19 Lubberts E, Joosten LAB, Helsen MMA, van den Berg WB. Regulatory role of interleukin 10 in joint inflammation and cartilage destruction in murine streptococcal cell wall (SCW) arthritis. More therapeutic benefit with IL-4/IL-10 combination therapy than with IL-10 treatment alone. Cytokine 1998;10:361-9.
20. 20 Matthys P, Vermeire K, Mitera T, Heremans H, Huang S, Billiau A. Anti-IL-12 antibody prevents the development and progression of collagen-induced arthritis in IFN-γ receptor-deficient mice. Eur J Immunol 1998;28:2143-51.
21. 99mTc-pertechnetate uptake. Agents Actions 1981;11: 640-2.
22. 22 Oluyomi AO, Nguyen H, Towbin H, Dawson J, Vosbeck K. Differential effects of prednisolone and indomethacin on zymosan-induced inflammation in a modified murine tissue-chamber model. Inflamm Res 1995;44:350-6.
23. 23 Drenth JPH, van Uum SMH, van Deuren M, Pesman GJ, van der Ven-Jongekrijg J, van de Meer JWM. Endurance run increases circulating IL-6 and IL-1Ra but down regulates ex vivo TNFα and IL-1β production. J Appl Physiol 1995;79:1497-503.
24. 24 Van Meurs JBJ, van Lent PLEM, Joosten LAB, van der Kraan PM, van den Berg WB. Quantification of mRNA levels in joint capsule and articular cartilage in the murine knee joint by RT-PCR. Rheumatol Int 1997;16:197-205.
25. 25 Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB. Anti-cytokine treatment of established collagen type II arthritis in DBA/1 mice: A comparative study using anti-TNFα, anti-IL-1α/β and IL-1ra. Arthritis Rheum 1996;39:797-809.
26. 26 Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
27. 27 Kanangat S, Blair P, Reddy R, Deheshia M, Godfrey V, Rose BT, et al. Disease in the scurfy (sf) mouse is associated with overexpression of cytokines genes. Eur J Immunol 1996;26: 161-7.
28. 28 Joosten LAB, Lubberts E, Helsen MMA, van den Berg WB. Dual role of interleukin-12 in early and late stages of murine collagen type II arthritis. J Immunol 1997;159: 4094-102.
29. 29 Lawrence C, Nauciel C. Production of interleukin-12 by murine macrophages in response to bacterial peptidoglycan. Infect Immun 1998;66:4947-9.
30. 30 Van den Berg WB, Joosten LAB, Helsen MMA, van Lent PLEM, van de Loo FAJ. Cytokine profile dependent on the type of arthritis: dominant role of IL-1 in cartilage destruction. Arthritis Rheum 1994;37:S279.
31. 31 Van den Berg WB, Kollias G, Joosten LAB, van de Loo FAJ. Relative role of IL-1 and TNF in SCW arthritis: studies in IL-1β and TNFα knockout mice. Arthritis Rheum 1998;41:S1908.
32. 32 Williams RO, Feldmann M, Maini RN. Anti-TNF ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992;89:9784-8.
33. 33 Boissier M-C, Chiocchia G, Bessis N, Hajnal J, Garotta G, Nicoletti F, et al. Biphasic effect of interferon-γ in murine collagen-induced arthritis. Eur J Immunol 1995;25:1184-90.
34. 34 Van de Loo FAJ, Joosten LAB, van Lent PLEM, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor I, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Arthritis Rheum 1995;38: 164-72.
35. 35 Lakshmi Rao K, Varalakshmi CH, Mubarak Ali A, Khar A. Administration of anti-IL-12 antibody in vivo inhibits rejection of a rat histocytoma and suppresses cytokine response in a tumour-bearing host. Immunology 1997;92: 381-7.
36. 36 Taskiran D, Stefanovic-Racic M, Georgescu H, Evans C. Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochem Biophys Res Commun 1994;200:142-8.
37. 37 Van de Loo FAJ, Arntz OJ, van Enckevort FHJ, van Lent PLEM, van den Berg WB. Reduced cartilage proteoglycan loss during zymosan-induced gonarthritis in NOS2 deficient mice and in anti-interleukin-1 treated wild-type mice with unabated joint inflammation. Arthritis Rheum 1998; 41:634-6.
38. 38 Palmer RMJ, Hickery MS, Charles IG, Moncade S, Bayliss MT. Induction of nitric oxide synthase in human chondrocytes. Biochem Biophys Res Commun 1993;193:398-405.
39. 39 Sakurai H, Kohsaka H, Liu MF, Higashiyama H, Hirata Y, Kanno K, et al. Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritis. J Clin Invest 1995;96:2357-63.
40. 40 Dodge GR, Diaz A, Sanz-Rodrigues C, Reginato AM, Jimenez SA. Effects of interferron-γ and tumor necrosis factor α on the expression of the genes encoding aggrecan, biglycan and decorin core proteins in cultured human chondrocytes. Arthritis Rheum 1998;41:274-83.
41. 41 Huang F-P, Feng G-J, Lindop G, Stott DI, Liew FY. The role of interleukin-12 and nitric oxide in the development of spontaneous autoimmune disease in MRL-MR-1pr/1pr mice. J Clin Invest 1996;183:1447-59.
42. 42 Seitz M, Loetscher P, Dewald B, Towbin H, Baggiolini M. Opposite effects of interleukin-13 and interleukin-12 on the release of inflammatory cytokines, cytokine inhibitors and prostaglandin E from synovial fibroblasts and blood mononuclear cells. Eur J Immunol 1996;26:2198-202
43. 43 Parks E, Strieter RM, Lukacs NW, Gauldie J, Hitt M, Graham FL, et al. Transient gene transfer of IL-12 regulates chemokine expression and disease severity in experimental arthritis. J Immunol 1998;160:4615-19.
44. 44 Walmsley M, Katsikis PD, Abney M, Katsikis E, Parry S, Williams RO, et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996;39:495-503.
45. 45 Willems F, Marchant A, Delwille JP, Gerard C, Delvaux A, Velu T, et al. Interleukin-10 inhibits B7 and intercellular adhesion molucule-1 expression on human monocytes. Eur J Immunol 1994;24:1007-9.
46. 46 Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
47. 47 Trinchieri G. Immunobiology of interleukin-12. Immunol Res 1998;17:269-78.
48. 48 Hodge-Dufour J, Noble PW, Horton MR, Bao C, Wysoka M, Burdick MD, et al. Induction of IL-12 and chemokines by hyaluronan requires adhesion-dependent priming of resistant but not elicited macrophages. J Immunol 1997; 159:2492-500.
49. 49 Cope AP, Sønderstrup G. Evaluating candidate autoantigens in rheumatoid arthritis. Spinger Semin Immunopathol 1998;20:23-39.
50. 50 Neurath MF, Fuss I, Kelsall BL, Struber E, Strober W. Antibodies to interleukin-12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90.
51. 51 Trembleau S, Penna G, Bosi E, Mortara A, Gately MK, Adorini L. Interleukin-12 administration induces T helper type I cells and accelerates autoimmune diabetes in NOD mice. J Exp Med 1995;181:817-21.
52. 52 Leonard JP, Waldburger KE, Goldman SJ. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin-12. J Exp Med 1995;181:381-6.